medpagetoday news

Pediatric Follicular Lymphoma: How Does it Differ from FL in Adults?

Follicular lymphoma is much less common in children than adults, but it does present in unique ways that community oncologists could benefit from recognizing, says Brian Hill, MD, PhD, of Cleveland Clinic. (1:41)

B-Cell Lymphoma: A Heterogenous Disease


Treating to Cure in DLBCL: The Risk of AML

Non-Hodgkin Lymphoma Subtypes and Prediagnostic Circulating Immune Markers

This study is reportedly the first to investigate associations between circulating immune markers and risk of non-Hodgkin lymphoma (NHL), across both common and rarer NHL subtypes and across different periods of follow-up.

In Women with DLBCL, Chronotherapy Improves Outcomes

This retrospective study demonstrated improved outcomes (progression-free survival and overall survival) in female patients with diffuse large B-cell lymphoma who received chemotherapy in the afternoon rather than in the morning.
medpagetoday news

Q&A: Possible Precursors to Follicular Lymphoma

Joe Schroers-Martin, MD, and Ash A. Alizadeh, MD, PhD, from Stanford University, discuss recent research into pre-diagnostic mutations that may help predict future disease.

Q&A: Shyam A. Patel, MD, PhD, on DLBCL — Where We Are and Where We’re Headed

In this interview, Dr. Patel discusses the curative potential of novel therapeutic agents, issues with tolerability, and improvements he expects in the next few years.

Understanding Duodenal-type Follicular Lymphoma


Biomarkers in Follicular Lymphoma

Q&A: Jeff R. Gehlhausen, MD, PhD, on Random Skin Biopsies in the Diagnosis of Intravascular Large B-cell Lymphoma

In an interview with MedPage Today, Dr. Gehlhausen, of the Yale School of Medicine, discussed the use of this diagnostic tool, describing the techniques that are available and important considerations.

Q&A: Thomas S.C. Ng, MD, PhD, and Antonio R. Lopez on Neurolymphomatosis in Diffuse Large B-cell Lymphoma

Dr. Ng and Mr. Lopez discuss the diagnosis of this rare lymphoma manifestation in an interview with MedPage Today.

Q&A: Sendhilnathan Ramalingam, MD, on Follicular Lymphoma Prognosis

Dr. Ramalingam discusses the utility of prognostic indicators such as tumor grade, mutational status, and more in follicular lymphoma.
medpagetoday news

In Follicular Lymphoma, What are the Risk Factors for Histological Transformation?

Utilizing data from the GALLIUM trial, investigators identified several risk factors for histological transformation of follicular lymphoma in a recent secondary analysis.

Low/Intermediate FLIPI and Not Transformed Follicular Lymphoma Has a Favorable Outcome

This retrospective analysis of patients with follicular lymphoma found that a Follicular Lymphoma International Prognostic Index low/intermediate score in the absence of histological transformation was associated with a good prognosis even for patients with early relapse.

Progression Within 24 Months Predicts Poorer Survival Following Relapse or Progression in Follicular Lymphoma

Patients with FL who experience disease progression within 24 months of first-line therapy have poorer overall survival compared with those who do not have progression within 24 months.